Trans dermal estrogen (oestrogel) for endometrial preparation in freeze embryo transfer cycle: An RCT

Ensieh Shahrokh Tehraninejad, Roya Kabodmehri, Batol Hosein Rashidi, Mina Jafarabadi, Fateme Keikha, Masomeh Masomi, Fedieh Hagholahi, Ensieh Shahrokh Tehraninejad, Roya Kabodmehri, Batol Hosein Rashidi, Mina Jafarabadi, Fateme Keikha, Masomeh Masomi, Fedieh Hagholahi

Abstract

Background: Estrogen and progesterone are two crucial factors for endometrial preparation in frozen embryo transfer (FET) cycles. Studies assessing different forms of estradiol in FET have published already but literature lacks enough surveys on transdermal estrogen application in reproductive medicine.

Objective: To investigate the effects of trans dermal estrogen (Oestrogel) on pregnancy rates in patients that candidate for FET cycle.

Materials and methods: In this randomized clinical trial, 100 women undergoing FET cycles referred to Imam Khomeeini Hospital were enrolled in two groups, randomly. Group I received 8 mg/day estradiol valerate (E2 tablet) orally and group II were treated with 6 mg/day transdermal oestrogel gel after suppression with gonadotropin releasing hormone agonist. In both groups medication were started in the first day of menstruation cycle and continued until endometrial thickness reached 8 mm. Pregnancy rates (chemical, clinical, and ongoing), abortion rate, live birth rate, and frequency of complications were compared between two groups.

Results: Chemical and clinical pregnancy rates were not significantly different between two groups (p=0.384). The abortion rate was significantly lower in group II than group I (p=0.035). Ongoing pregnancy and the live birth rates were significantly higher in group II (p=0.035). The rate of complication was not different in two groups.

Conclusion: Oestrogel seems to enhance ongoing pregnancy and live birth rates in comparison to estradiol valerate tablet.

Keywords: Estradiol valerate GnRH analogue; FET cycle; Transdermal estrogen.

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Consort flow chart.

References

    1. Gardner DK, Weissman A, Howles CM, Shoham Z. Textbook of Assisted Reproductive Techniques. 4th Ed. Clinical Perspectives, CRC press; 2012.
    1. Nygren KG, Sullivan E, Zegers-Hochschild F, Mansour R, Ishihara O, Adamson GD, et al. International Committee for Monitoring Assisted Reproductive Technology (ICMART) world report: assisted reproductive technology 2003. Fertil Steril. 2011;95:2209–2222.
    1. Muasher SJ, Kruithoff C, Simonetti S, Oehninger S, Acosta AA, Jones GS. Controlled preparation of the endometrium with exogenous steroids for the transfer of frozen-thawed pre-embryos in patients with anovulatory or irregular cycles. Hum Reprod. 1991;6:443–445.
    1. Devroey P, Pados G. Preparation of endometrium for egg donation. Hum Reprod Update. 1998;4:856–861.
    1. Devroey P, Wisanto A, Camus M, Van Waesberghe L, Bourgain C, Liebaers I, et al. Oocyte donation in patients without ovarian function. Hum Reprod. 1988;3:699–704.
    1. Rosenwaks Z. Donor eggs: their application in modern reproductive technologies. Fertil Steril. 1987;47:895–909.
    1. Devroey P, Smitz J, Camus M, Wisanto A, Deschacht J, Van Waesberghe L, et al. Synchronization of donor's and recipient's cycles with GnRH analogues in an oocyte donation programme. Hum Reprod. 1989;4:270–274.
    1. Van SA, Pados G, Devroey P, Bonduelle M, Van AE, Liebaers I. Oocyte donation for genetic indications. Reprod Fertil Develop. 1992;4:681–688.
    1. Schmidt CL, de Ziegler D, Gagliardi CL, Mellon RW, Taney FH, Kuhar MJ, et al. Transfer of cryopreserved-thawed embryos: the natural cycle versus controlled preparation of the endometrium with gonadotropin-releasing hormone agonist and exogenous estradiol and progesterone (GEEP) Fertil Steril. 1989;52:609–616.
    1. Ghobara T, Vanderkerchove P. Cycle regimens for frozen‐thawed embryo transfer. Cochrane Database Syst Rev. 2008;1:CD003414.
    1. Van Keep PA, Utian WH, Vermeulen A. Potency and hepato-cellular effects of oestrogens after oral, percutaneous, and subcutaneous administration. The Controversial Climacteric . 1982:103–125.
    1. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol. 1985;152:1099–1106.
    1. Dal Prato L, Borini A, Cattoli M, Bonu MA, Sciajno R, Flamigni C. Endometrial preparation for frozen-thawed embryo transfer with or without pretreatment with gonadotropin-releasing hormone agonist. Fertil Steril. 2002;77:956–960.
    1. Remohi J, Vidal A, Pellicer A. Oocyte donation in low responders to conventional ovarian stimulation for in vitro fertilization. Fertil Steril. 1993;59:1208–1215.
    1. Ryan KJ, Engel LL. The interconversion of estrone and estradiol by human tissue slices. Endocrinology. 1953;52:287–291.
    1. Davies MC, Anderson MC, Mason BA, Jacobs HS. Oocyte donation: the role of endometrial receptivity. Hum Reprod. 1990;5:862–869.
    1. Mandel FP, Geola FL, Meldrum DR, Lu JH, Eggena P, Sambhi MP, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab. 1983;57:133–139.
    1. Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. lippincott Williams & wilkins; 2005.
    1. Casper RF, Yanushpolsky EH. Optimal endometrial preparation for frozen embryo transfer cycles: window of implantation and progesterone support. Fertil Steril. 2016;105:867–872.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa